SUBSCRIBERS
Trendlines Group still a 'buy': DBS research
Add BT as a preferred sourcePublished Thu, Mar 17, 2016 · 09:50 PM
Singapore
DBS Group Research has maintained its buy rating on The Trendlines Group, despite the Catalist-listed medical (medtech) and agricultural tech (agtech) incubator losing the bid to renew its agtech incubator licence.
It is "not a material loss", DBS analyst Sachin Mittal said in a note on Thursday. "Given that medtech companies comprise an estimated 70-80 per cent of Trendlines' portfolio value, this should not be a big concern."
Share with us your feedback on BT's products and services
